May 06, 2022
Video
In the first episode of this new game show, a team of ARVO 2022 investigators work to invent an innovative clinical trial.
May 05, 2022
From curative stem cell approaches to in-clinic subretinal injections, Arshad Khanani, MD, MA, navigates what the future drug class may entail.
An FDA decision could come as soon as this year. One expert stresses the need for improved screening, biomarker research, and patient communication beforehand.
Study author Arshad Khanani, MD, MA, discusses how the novel-targeting gene therapy candidate may uniquely benefit patients with treated retina disease.
May 04, 2022
Theodore Leng, MD, MS, discusses his team's IRIS registry findings suggesting a need for quantifying how vision-loss patients are impacted by functional or quality-of-life measures.
Article
Data show half of all eyes with CRVO were still being treated at 36-months.
Treatment delay and steroid usage were both associated with worse improvements in long term BVA and CST in patients with RVO-related macular edema.
May 03, 2022
Veeral S. Sheth, MD, MBA, gives an update on his practice's adoption of the novel PDS in patients with AMD—and discusses other potential methods of anti-VEGF delivery.
These data further elucidate the relationship between mental health and diabetic retinopathy.
However, data show RVO patients with clinical findings associated with glaucoma risk are often not coded with suspected glaucoma.
Patients With Vitiligo Report Varied Severe Symptoms Based on Skin Tone
Ruxolitinib Beneficial Across Demographics of Patients with Vitiligo
Promising Data from InPedILD Phase 3 Trial Revealed at ERS Congress 2022
